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INTRODUCTION
The human body is colonized by a wide
variety of micro-organisms, which are
known to play an important role in regula-
tion of metabolic functions and maintain-
ing immune homeostasis. Instantaneously
after birth, skin surface, oral cavity, and gut
are settled by extensive range of microbes,
mainly bacteria, but also archaea, fungi,
viruses, and protozoa. Commonly called
human microbiota, it consists of trillions
of organisms from over 1000 species. The
most abundant species are members of
the phyla Bacteroidetes and Firmicutes. An
important number of studies have been
undertaken to determine if the gut micro-
biota is a promising target for clinical treat-
ment or prevention. In the current issue of
Frontiers in Medicine – Gastroenterology,
Nagpal et al. paid close attention to the role
of gut in health and disease. In their paper,
they raise important questions and pay par-
ticular attention to ambiguities, which still
remain to be elucidated to proper under-
standing of the complexity of human–
microbe relationships. To better translate
and apply current knowledge in clinical
practice, answering the queries about com-
positional alterations in gut microbiome by
diet or during diseases is necessary.
ROLE OF GUT MICROBIOTA IN HEALTH
AND DISEASE
Bacterial diversity changes with age (1). As
stated earlier, the adult gut ecosystem is
dominated particularly by Firmicutes and
Bacteroidetes phyla, but also by Actinobac-
teria, Proteobacteria, and Verrucomicrobia
(2, 3); the anaerobic bacteria include Bifi-
dobacterium spp and Faecalibacterium spp.
It is important to emphasize that oxygen-
tolerant bacteria, such as Lactobacillus spp.
and members of Proteobacteria phylum
may also appear in the gut, but in a low
number. The population of aerobic bac-
teria is fluctuating over time and depends
on diet and other environmental factors,
such as hygiene, climate, geography, and
ethnicity (4). The influence of nutrients
on microbiome diversity was affirmed in
the study by De Filippo et al. (5), in which
Western diet in European children, high in
animal protein and fat, caused reduction
in short chain fatty acid-producing bac-
teria and increased the number of poten-
tially pathogenic organisms in compari-
son to low animal protein diet and high-
carbonate used by children in rural Africa.
Nagpal et al. exposed the importance of
diet in microbiota gentle alterations and
the necessity of defining the ideal dietary
macronutrients composition (ratios and
types of carbohydrates, fats, and proteins).
Changes in gut microbiota in various
types of diseases, such as obesity, IBD,
type 2 diabetes, and non-alcoholic fatty
liver disease is another problem raised
by Nagpal et al. Gut microbiota dys-
biosis causes increased gut permeability,
systemic inflammation, and insulin resis-
tance. Recent studies showed that patients
suffering from IBD harbor altered gut
microbiota, especially a reduced bacteria
diversity (6, 7). In line, a decreased number
of the butyrate-producing bacteria Rose-
buria hominis and Faecalibacterium praus-
nitzii have been observed in ulcerative col-
itis patients in comparison to control indi-
viduals (8). Of note, gut microbiota dysbio-
sis and lower levels of butyrate-producing
bacteria were also observed in diabetes type
2 patients (9).
GUT MICROBIOTA AS A NEW
TREATMENT TARGET
Nagpal et al. underlined that numerous
studies are conducted to indicate the ther-
apeutic role of dietary supplements on gut
microbiota and only after a precise identi-
fication of the role of each gut microbial
family we could manipulate it by reduc-
ing the type and number of harmful and
increasing beneficial populations. Several
known therapeutics, such as prebiotics,
probiotics, and antibiotics, can alternate
the microbiota diversity.
Probiotics are defined by WHO as “live
organisms, which – when administered
in adequate amounts – confer a health
benefit on the host.” The main micro-
organisms used as probiotics are Lacto-
bacillus and Bifidobacterium. Several stud-
ies suggest that probiotics improve intesti-
nal barrier function, modulate the immune
system, and enhance the host defense
system against pathogens (10). In addition,
probiotic intervention plays a positive role
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in prevention or improvement of some gas-
trointestinal diseases, such as IBD (11) and
necrotizing enterocolitis (12).
Prebiotics are non-viable food compo-
nents that confer health benefits on the
host associated with modulation of micro-
biota (13). Thus prebiotics are dietary
compounds, particularly insulin, fruc-
tooligosaccharides, and glucooligosaccha-
rides, which have an impact on local gut
bacterial microbiota. In the gut, prebiotics
enhance the colonization of beneficial bac-
teria, such as Lactobacillus and Bifidobac-
terium and also stimulate immunity and
prevent the adhesion of pathogens (10).
Finally, in their paper Nagpal et al. raise
an important issue of the fecal transplant,
which may become the therapy of the
future. Fecal transplantation is a process
of transferring fecal bacterial communi-
ties from healthy individuals to a recipi-
ent, whose microbiota have been disrupted.
Nowadays, fecal transplantation has been
used to treat recurrent Clostridium diffi-
cile infection by restoring the microbiota
whipped out by the use of antibiotics. Even
though a variety of problems in estab-
lishing the state of the art technique in
fecal transplantation exist, the results are
promising. Systematic literature review by
Gough et al. to examine the effect of
fecal transplant on 317 Clostridium diffi-
cile infected patients revealed that disease
was resolved in 92% of cases (9).
CONCLUSION
The gut microbiota is a complex ecosys-
tem,which in a healthy state provides major
functions to the host by influencing metab-
olism, modulating the immune system, and
protecting against pathogens. Nowadays,
the most important research task is to gain
a deeper understanding of the complex
relationships between the gut microbiota
and disease. Nagpa et al. clearly show that
gut microbiota is a promising target for
preventive and therapeutic treatment and
in a near future we will be able to use
individual microbiome profiles in clinical
practice to evaluate the current state and
function of the gut. The use of prebiotics
and probiotics, as well as in future the fecal
transplant gives the clinicians a unique tool
to treat chronic conditions, such as IBD,
obesity and type 2 diabetes.
ACKNOWLEDGMENTS
Supported by the Iuventus Plus program of
the Polish Ministry of Science and Higher
Education (#0107/IP1/2013/72 to Jakub
Fichna)andthegrantfromtheMedicalUni-
versity of Lodz (#503/1-156-04/503-01).
REFERENCES
1. Yatsunenko T, Rey FE, Manary MJ, Trehan I,
Dominguez-Bello MG, Contreras M, et al. Human
gut microbiome viewed across age and geog-
raphy. Nature (2012) 486:222–7. doi:10.1038/
nature11053
2. Arumugam M, Raes J, Pelletier E, Le PD, Yamada T,
Mende DR, et al. Enterotypes of the human gut
microbiome. Nature (2011) 473:174–80. doi:10.
1038/nature09944
3. Salonen A, Salojarvi J, Lahti L, de Vos WM. The
adult intestinal core microbiota is determined by
analysis depth and health status. Clin Microbiol
Infect (2012) 18(Suppl 4):16–20. doi:10.1111/j.
1469-0691.2012.03855.x
4. Marques TM, Cryan JF, Shanahan F, Fitzgerald GF,
Ross RP, Dinan TG, et al. Gut microbiota mod-
ulation and implications for host health: dietary
strategies to influence the gut-brain axis. Innov
Food Sci Emerg Technol (2014) 22:239–47. doi:10.
1016/j.ifset.2013.10.016
5. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti
M, Poullet JB, Massart S, et al. Impact of diet in
shaping gut microbiota revealed by a comparative
study in children from Europe and rural Africa.
Proc Natl Acad Sci U S A (2010) 107:14691–6.
doi:10.1073/pnas.1005963107
6. Frank DN, St Amand AL, Feldman RA, Boedeker
EC, Harpaz N, Pace NR. Molecular-phylogenetic
characterization of microbial community imbal-
ances in human inflammatory bowel diseases.
Proc Natl Acad Sci U S A (2007) 104:13780–5.
doi:10.1073/pnas.0706625104
7. Sokol H, Seksik P. The intestinal microbiota in
inflammatory bowel diseases: time to connect
with the host. Curr Opin Gastroenterol (2010)
26:327–31. doi:10.1097/MOG.0b013e328339536b
8. Machiels K, Joossens M, Sabino J, De Preter V, Arijs
I, Eeckhaut V, et al. A decrease of the butyrate-
producing species Roseburia hominis and Faecal-
ibacterium prausnitzii defines dysbiosis in patients
with ulcerative colitis. Gut (2013). doi:10.1136/
gutjnl-2013-304833
9. Walsh CJ, Guinane CM, O’Toole PW, Cotter PD.
Beneficial modulation of the gut microbiota. FEBS
Lett (2014). doi:10.1016/j.febslet.2014.03.035
10. Saulnier DM, Spinler JK, Gibson GR, Versalovic
J. Mechanisms of probiosis and prebiosis: con-
siderations for enhanced functional foods. Curr
Opin Biotechnol (2009) 20:135–41. doi:10.1016/j.
copbio.2009.01.002
11. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-
Orenstein AE, Brandt LJ, et al. The efficacy of pro-
biotics in the treatment of irritable bowel syn-
drome: a systematic review. Gut (2010) 59:325–32.
doi:10.1136/gut.2008.167270
12. Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Pro-
biotics for prevention of necrotizing enterocol-
itis in preterm infants. Cochrane Database Syst
Rev (2011) 3:CD005496. doi:10.1002/14651858.
CD005496.pub3
13. Pineiro M, Asp NG, Reid G, Macfarlane S, Morelli
L, Brunser O, et al. FAO technical meeting on pre-
biotics. J Clin Gastroenterol (2008) 42(Suppl 3 Pt
2):S156–9. doi:10.1097/MCG.0b013e31817f184e
Conflict of Interest Statement: The authors declare
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 19 June 2014; accepted: 26 June 2014; published
online: 10 July 2014.
Citation: Zatorski H and Fichna J (2014) What
is the future of the gut microbiota-related treat-
ment? Toward modulation of microbiota in preven-
tive and therapeutic medicine. Front. Med. 1:19. doi:
10.3389/fmed.2014.00019
This article was submitted to Gastroenterology, a section
of the journal Frontiers in Medicine.
Copyright © 2014 Zatorski and Fichna. This is an open-
access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited
and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Medicine | Gastroenterology July 2014 | Volume 1 | Article 19 | 2
